Miragen Therapeutics, Inc. (NASDAQ:MGEN) Q1 2020 Earnings Conference Call - Final Transcript
May 07, 2020 • 04:30 pm ET
Greetings and welcome to the miRagen Therapeutics First Quarter 2020 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.
It is now my pleasure to introduce your host, Dan Ferry with LifeSci Advisors. Thank you, Mr. Ferry, you may begin.
Gentlemen, it looks like we may have lost Dan off the line just now.
Yeah. It asked us to provide our email address, and it asked us to record something.
Okay. That's something new. Mr. Ferry, are you with us? Okay. Rejoining Mr. Ferry.
Thank you, operator. Good afternoon, everyone, and welcome to our first quarter 2020 conference call. Today, after the close, we issued a press release providing our financial results and corporate update for the first quarter. A replay of today's call will be available on the Investors section of our website approximately one hour after its completion. After our prepared remarks, we will open the call for Q&A.
Before we begin, I would like to remind everyone that this conference call and webcast will contain forward-looking statements about the Company. These statements are subject to risks and uncertainties that could cause actual results to differ. Please note that these forward-looking statements reflect our opinions only as of today. Except as required by law, we specifically disclaim any obligation to update or revise these forward-looking statements in light of new information or future events. Factors that could cause actual results or outcomes to differ materially from those expressed in or implied by such forward-looking statements are discussed in greater detail in our most recent filings on Form 10-K, and our other periodic reports on forms 10-Q and 8-K filed with the SEC.
I would now like to turn the call over to miRagen's President and Chief Executive Officer, Bill Marshall.
William S. Marshall
Thank you, Dan. Good afternoon, everyone, and thank you for joining us for our corporate update call for the first quarter 2020. I'm joined today by Diana Escolar, our Chief Medical Officer, and Jason Leverone, our Chief Financial Officer.
We entered 2020 with a streamlined and more focused development strategy that we believe will help drive long-term shareholder value. Over the course of the past couple months, miRagen, along with the rest of the world, has had to face the far-reaching effects of the ongoing COVID-19 pandemic. In March, the miRagen leadership team was proactive in implementing steps to protect the health and wellbeing of our team, including practicing social distancing by having our administrative employees work from home and staggering shifts for essential lab employees. Our team has been quick to adapt to this new structure and I appreciate all their hard work and dedication to the continued advancement of our programs. However, as we look ahead, COVID-19 is or is expected to have some degree of impact on patients in our studies, certain clinical sites, external analytical functions and potentially regulators. As a result, we cannot confidently predict when we will achieve certain milestones.
With that said, let me take this opportunity to